{"entity":{"id":"nct00299689","kind":"trial","name":"Phase II Trial of Ontak With Metastatic Melanoma","aka":[],"tldr":"A phase 2 trial of Denileukin diftitox in Melanoma, run by James Graham Brown Cancer Center, completed.","summary":"Phase II Trial of Ontak With Metastatic Melanoma is a phase 2 interventional study registered as NCT00299689 by James Graham Brown Cancer Center, with 69 participants recorded, started 2006-03 and reaching its primary completion in 2010-01. Interventions recorded: Denileukin diftitox. Conditions recorded: Malignant Melanoma.\n\nLinked to the drug Denileukin diftitox because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00299689","url":"https://clinicaltrials.gov/study/NCT00299689"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["denileukin-diftitox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00299689","phase":"2","setting":"Phase II Trial of ONTAK With Metastatic Melanoma","sponsor":"James Graham Brown Cancer Center","enrolled":69,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00299689/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/"}]}}